{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:59Z","timestamp":1753891919899,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Liquid biopsies including pleural fluid or plasma are commonly applied for patients with advanced non-small cell lung cancer (NSCLC) and pleural effusion (PE) to guide the treatment. ALK-TKIs are the first options for patients with ALK-positive mutations and combining ALK-TKIs with angiogenic agents may improve survival. We report here one case with ALK-positive lung adenocarcinoma in which the patient achieved a prolonged progression-free survival (PFS) of 97 months after undergoing precise pleural effusion NGS and receiving combined bevacizumab treatment following multiple-line ALK-TKI resistance.<\/jats:p>","DOI":"10.3389\/fonc.2024.1419306","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T04:32:12Z","timestamp":1719203532000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: Precise NGS and combined bevacizumab promote durable response in ALK-positive lung adenocarcinoma with multiple-line ALK-TKI resistance"],"prefix":"10.3389","volume":"14","author":[{"given":"Jin","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31340-X","article-title":"Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease","volume":"388","author":"Hiley","year":"2016","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr","article-title":"Advancements of ALK inhibition of non-small cell lung cancer: a literature review","volume":"12","author":"Zia","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30129-7","article-title":"Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial","volume":"5","author":"Rosell","year":"2017","journal-title":"Lancet Respir Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0007-2017","article-title":"Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series \"Pathology for the clinician\" Edited by Peter Dorfm\u00fcller and Alberto Cavazza","volume":"26","author":"Bubendorf","year":"2017","journal-title":"Eur Respir Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7150\/thno.34070","article-title":"Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer","volume":"9","author":"Tong","year":"2019","journal-title":"Theranostics"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr","article-title":"A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer","volume":"9","author":"Jin","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.07.004","article-title":"Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers","volume":"13","author":"Drilon","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00268-003-7003-y","article-title":"Needle tract implantation of hepatocellular carcinoma and pancreatic carcinoma after ultrasound-guided percutaneous puncture: clinical and pathologic characteristics and the treatment of needle tract implantation","volume":"28","author":"Kosugi","year":"2004","journal-title":"World J Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2008.9.3.268","article-title":"Needle tract implantation after percutaneous interventional procedures in hepatocellular carcinomas: lessons learned from a 10-year experience","volume":"9","author":"Chang","year":"2008","journal-title":"Korean J Radiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605964","article-title":"Prevention of tumour cell dissemination in diagnostic needle procedures","volume":"103","author":"Wiksell","year":"2010","journal-title":"Br J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.09.006","article-title":"ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression","volume":"91","author":"Ou","year":"2016","journal-title":"Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discovery"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1511","article-title":"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib","volume":"20","author":"Katayama","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.02.014","article-title":"Lorlatinib for previously treated ALK-positive advanced NSCLC: Primary efficacy and safety from a phase 2 study in people's Republic of China","volume":"17","author":"Lu","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100508","DOI":"10.1016\/j.jtocrr.2023.100508","article-title":"A retrospective, multicenter, observational study to evaluate clinical outcomes of lorlatinib after alectinib in patients with ALK-positive NSCLC in Japan","volume":"4","author":"Goto","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0302","article-title":"Bevacizumab in advanced lung cancer: state of the art","volume":"13","author":"Assoun","year":"2017","journal-title":"Future Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00271","article-title":"Lorlatinib and bevacizumab activity in ALK-rearranged lung cancers after lorlatinib progression","volume":"4","author":"Choudhury","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100342","DOI":"10.1016\/j.esmoop.2021.100342","article-title":"Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I\/II study","volume":"7","author":"Lin","year":"2022","journal-title":"ESMO Open"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14801","article-title":"VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers","volume":"112","author":"Watanabe","year":"2021","journal-title":"Cancer Sci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1419306\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T04:32:15Z","timestamp":1719203535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1419306\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":25,"alternative-id":["10.3389\/fonc.2024.1419306"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1419306","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"article-number":"1419306"}}